Abstract
We present a unique case of a patient with a long-standing history of indolent chronic lymphocytic leukaemia (CLL) who suddenly developed autoimmune haemolytic anaemia after starting immune checkpoint inhibitor therapy for bladder cancer. He had no clear indication to start CLL-directed treatment based on current clinical practice guidelines; however, targeted treatment of CLL with ibrutinib proved to be effective in treating the haemolytic anaemia.
Reference30 articles.
1. Autoimmune cytopenias in chronic lymphocytic leukemia
2. Immune-Mediated hemolytic anemia and thrombocytopenia in clonal B-cell disorders: a review;Durani;Clin Adv Hematol Oncol,2018
3. U.S. food and drug administration: FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer. Available: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer [Accessed 19 Apr 2021].
4. Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs;Vitale;Cancers,2020
5. Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献